The addition of chemotherapy in the definitive management of high risk prostate cancer

In attempt to improve disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX) —either adjuvant or neoadjuvant—to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT).

Source: Urologic Oncology: Seminars and Original Investigations - October 8, 2018 Category: Urology & Nephrology Authors: Matthew J. Ferris, Yuan Liu, Jingning Ao, Jim Zhong, Mustafa Abugideiri, Theresa W. Gillespie, Bradley C. Carthon, Mehmet A. Bilen, Omer Kucuk, Ashesh B. Jani Tags: Review article Source Type: research